毛细胞白血病：过去、现在与未来
Hairy cell leukemia: Past, present and future.
作者信息
Getta Bartlomiej M, Park Jae H, Tallman Martin S
机构信息
Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York 10065, USA.
Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York 10065, USA; Weill Cornell Medical College, 1305 York Avenue, New York 10021, USA.
出版信息
Best Pract Res Clin Haematol. 2015 Dec;28(4):269-72. doi: 10.1016/j.beha.2015.10.015. Epub 2015 Oct 21.
Abstract
This brief review highlights the sequence of therapeutic milestones and advances in our understanding of the biology of hairy cell leukemia (HCL) with a focus on recent molecular findings and how these may be applied to improve disease outcomes in the future. Targeted therapy is discussed in the context of the recently identified BRAF mutation and other genetic findings.
摘要
本简要综述重点介绍了毛细胞白血病（HCL）治疗里程碑的先后顺序以及我们对其生物学认识的进展，着重关注近期的分子研究发现以及这些发现如何应用于未来改善疾病预后。在最近发现的BRAF突变及其他遗传学发现的背景下讨论了靶向治疗。
相似文献
1
Hairy cell leukemia: Past, present and future.毛细胞白血病：过去、现在与未来
Best Pract Res Clin Haematol. 2015 Dec;28(4):269-72. doi: 10.1016/j.beha.2015.10.015. Epub 2015 Oct 21.
2
Historical overview of hairy cell leukemia.毛细胞白血病的历史概述。
Best Pract Res Clin Haematol. 2015 Dec;28(4):166-74. doi: 10.1016/j.beha.2015.10.018. Epub 2015 Oct 26.
3
Hairy cell leukemia.毛细胞白血病
Best Pract Res Clin Haematol. 2015 Dec;28(4):163-5. doi: 10.1016/j.beha.2015.10.021. Epub 2015 Nov 11.
4
Long-term follow-up after purine analogue therapy in hairy cell leukaemia.毛细胞白血病嘌呤类似物治疗后的长期随访
Best Pract Res Clin Haematol. 2015 Dec;28(4):217-29. doi: 10.1016/j.beha.2015.09.004. Epub 2015 Oct 9.
5
Hairy cell leukemia: update and current therapeutic approach.毛细胞白血病：最新进展与当前治疗方法
Curr Opin Hematol. 2015 Jul;22(4):355-61. doi: 10.1097/MOH.0000000000000154.
6
Chemoimmunotherapy for hairy cell leukemia.毛细胞白血病的化学免疫疗法。
Best Pract Res Clin Haematol. 2015 Dec;28(4):230-5. doi: 10.1016/j.beha.2015.09.005. Epub 2015 Oct 8.
7
New insights in the management of patients with hairy cell leukemia.毛细胞白血病患者管理的新见解。
Curr Opin Oncol. 2015 Sep;27(5):371-6. doi: 10.1097/CCO.0000000000000214.
8
BRAF inhibitor therapy in HCL.毛细胞白血病中的BRAF抑制剂疗法。
Best Pract Res Clin Haematol. 2015 Dec;28(4):246-52. doi: 10.1016/j.beha.2015.10.001. Epub 2015 Oct 20.
9
BRAF inhibition in refractory hairy-cell leukemia.BRAF抑制在难治性毛细胞白血病中的应用
N Engl J Med. 2012 May 24;366(21):2038-40. doi: 10.1056/NEJMc1202124.
10
Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.低剂量维莫非尼使一例伴有V600E突变的毛细胞白血病患者实现完全缓解。
Haematologica. 2013 Feb;98(2):e20-2. doi: 10.3324/haematol.2012.082404. Epub 2013 Jan 8.
引用本文的文献
1
Resistance to antibody-drug conjugates: A review.抗体药物偶联物的耐药性：综述
Acta Pharm Sin B. 2025 Feb;15(2):737-756. doi: 10.1016/j.apsb.2024.12.036. Epub 2024 Dec 31.
2
Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy.维莫非尼单药治疗复发/难治性毛细胞白血病患者的长期疗效。
Blood. 2022 Dec 22;140(25):2663-2671. doi: 10.1182/blood.2022016183.
3
Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib.经典型毛细胞白血病并发全血细胞减少症和严重感染：维莫非尼治疗 3 例报告。
Blood Adv. 2019 Jan 22;3(2):116-118. doi: 10.1182/bloodadvances.2018027466.
4
Moxetumomab Pasudotox: First Global Approval.注射用米托蒽醌单抗：全球首次获批
Drugs. 2018 Nov;78(16):1763-1767. doi: 10.1007/s40265-018-1000-9.
5
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.泊马度胺治疗复发/难治性毛细胞白血病。
Leukemia. 2018 Aug;32(8):1768-1777. doi: 10.1038/s41375-018-0210-1. Epub 2018 Jul 20.
6
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of V600E Mutation in Hairy Cell Leukemia.液滴数字PCR：一种用于评估毛细胞白血病中V600E突变的新型有效分子方法。
Front Pharmacol. 2016 Oct 13;7:363. doi: 10.3389/fphar.2016.00363. eCollection 2016.
本文引用的文献
1
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.靶向复发性或难治性毛细胞白血病中的突变型BRAF
N Engl J Med. 2015 Oct 29;373(18):1733-47. doi: 10.1056/NEJMoa1506583. Epub 2015 Sep 9.
2
Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.毛细胞白血病：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2015 Sep;26 Suppl 5:v100-7. doi: 10.1093/annonc/mdv200. Epub 2015 Aug 12.
3
Recurrent CDKN1B (p27) mutations in hairy cell leukemia.复发性毛细胞白血病中的 CDKN1B（p27）突变。
Blood. 2015 Aug 20;126(8):1005-8. doi: 10.1182/blood-2015-04-643361. Epub 2015 Jun 11.
4
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.BRAF抑制剂可逆转毛细胞白血病独特的分子特征和表型，并发挥强大的抗白血病活性。
Blood. 2015 Feb 19;125(8):1207-16. doi: 10.1182/blood-2014-10-603100. Epub 2014 Dec 5.
5
The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.布鲁顿酪氨酸激酶抑制剂依鲁替尼（PCI-32765）可阻断毛细胞白血病的存活、增殖及B细胞受体信号传导：一种新的治疗方法。
Br J Haematol. 2014 Jul;166(2):177-88. doi: 10.1111/bjh.12867. Epub 2014 Apr 2.
6
Left behind: should minimal residual disease be treated in hairy cell leukemia?遗留问题：毛细胞白血病中微小残留病是否应接受治疗？
Leuk Lymphoma. 2014 May;55(5):971-2. doi: 10.3109/10428194.2013.866667. Epub 2014 Mar 7.
7
Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias.BRAF V600E 阴性毛细胞白血病中的 BRAF 替代突变。
Br J Haematol. 2014 May;165(4):529-33. doi: 10.1111/bjh.12735. Epub 2014 Jan 16.
8
High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias.高表达 MAP2K1 突变的变异型和 IGHV4-34 表达的毛细胞白血病。
Nat Genet. 2014 Jan;46(1):8-10. doi: 10.1038/ng.2828. Epub 2013 Nov 17.
9
Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC).初始采用嘌呤类似物治疗的毛细胞白血病：来自西班牙慢性淋巴细胞白血病协作组（GELLC）的107例患者的回顾性研究
Leuk Lymphoma. 2014 May;55(5):1007-12. doi: 10.3109/10428194.2013.827187. Epub 2013 Sep 16.
10
BRAF inhibition in refractory hairy-cell leukemia.BRAF抑制在难治性毛细胞白血病中的应用
N Engl J Med. 2012 May 24;366(21):2038-40. doi: 10.1056/NEJMc1202124.
Zotero 插件